SCHEDULE: Synlogic, Inc. Merger Support Agreement Filed

Reporting persons Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma-Weaver have filed an amendment to their Schedule 13D, detailing their support for Synlogic's merger with Caldera Therapeutics, Inc.

Summary

• An amendment to a Schedule 13D filing has been submitted concerning Synlogic, Inc.
• The filing details a Support Agreement entered into by Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma-Weaver (collectively, the Reporting Persons) on July 28, 2026.
• This agreement supports the merger between Synlogic, Inc. and Caldera Therapeutics, Inc., as outlined in an Agreement and Plan of Merger.
• The Reporting Persons collectively own 3,312,219 shares of Synlogic, Inc. common stock, representing 28.3% of the class.
• Under the Support Agreement, the Reporting Persons have committed to vote their shares in favor of the merger and related proposals.
• They have also agreed not to sell or transfer their shares (with exceptions), grant proxies, or exercise appraisal rights concerning the merger.
• An irrevocable proxy has been granted to Synlogic, Inc. to vote the shares on supported matters, subject to certain conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily confirms existing agreements and shareholder support for a previously announced transaction, rather than introducing new financial or strategic information.

Positives

• The Reporting Persons, holding a significant 28.3% stake, are formally supporting the proposed merger, which can aid in its approval.
• The Support Agreement provides clarity and commitment from major shareholders regarding the merger transaction.

Negatives

• The Reporting Persons are restricted from selling or transferring their shares, limiting their immediate liquidity options.
• The irrevocable proxy limits the Reporting Persons' ability to independently exercise their voting rights on other matters.

Risks

• The merger agreement could be terminated, which would also terminate the Support Agreement.
• The Reporting Persons are restricted from selling shares, which could be a disadvantage if market conditions change unfavorably before the merger closes.

Future Outlook

The filing does not contain forward-looking statements or guidance; it primarily concerns the execution of a merger agreement and related support.

Management Comments

• The Reporting Persons have agreed to vote all of their Shares in favor of the Merger and the adoption of the Merger Agreement.
• The Reporting Persons have agreed not to take certain actions, including selling or transferring any Shares (subject to certain exceptions).

Industry Context

StockSavvy.ai notes that this filing reflects a common strategy where significant shareholders formally commit to supporting a merger, aiming to ensure its successful completion and provide certainty to the market.

Stakeholder Impact

• Shareholders: The merger is expected to result in shareholders receiving consideration as per the Merger Agreement. The support from major shareholders may increase confidence in the merger's completion.
• Management and Employees: The merger will likely lead to changes in corporate structure and potentially employment terms, depending on the integration plans of the acquiring entity.
• Creditors: The financial stability and obligations of the combined entity will be a key consideration for creditors.

Next Steps

• The merger between Synlogic, Inc. and Synlogic Merger Sub (a subsidiary of Parent) is expected to proceed, subject to the terms of the Merger Agreement.
• The Reporting Persons will vote their shares in favor of the merger.

Key Dates

Recommendation

The filing confirms support for an existing merger agreement, which is a known event. While it reduces uncertainty regarding shareholder approval, it does not introduce new information that would fundamentally alter the investment thesis for Synlogic's stock at this stage. A 'hold' recommendation reflects the ongoing nature of the merger process and the lack of new material financial performance data.

Keywords

Merger Agreement, Support Agreement, Schedule 13D, Synlogic, Caldera Therapeutics, Shareholder Vote, Beneficial Ownership, Proxy